Evotec Se · XETR:EVT
Evotec — Baader Investment Conference 2020
26 slides from Evotec's conference presentation, Sep 21, 2020
Slide 1: Evotec: Partnered Drug Discovery and Development
Evotec Partnered Drug Discovery and Development Evotec SE, Company Presentation, Baader Investment Conference, 21 September 2020
Slide 2: Forward-looking statement
Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking sta
Slide 3: Mastering COVID-19
#Researchneverstops Mastering COVID-19 What is paramount in this situation Protect Respect Focus Help Involved in multiple activities to combat COVID-19 NIH-led initiative Accelerating COVID-19 Therapeutic Interventions and Vaccines (“ACTIV”) “COVID R&D”, global initiative, leading repurposing w
Slide 4: Agenda
Agenda Overview Partnered drug discovery & development Financials & Outlook PAGE 3
Slide 5: More than 3,350 x unique expertise
More than 3,350 x unique expertise Global centres of excellence Abingdon, Alderley Park ~800 employees 1st J.POD1) Hamburg Headquarters, Cologne, Göttingen, Munich ~800 employees Orth an der Donau, Austria ~30 employees Verona Princeton, Seattle, Lyon, Toulouse ~700 employees Branford, Watertown ~33
Slide 6: Leading the external innovation megatrend
Leading the external innovation megatrend Company snapshot – Development from 2015 … 2019 Co-owned programmes with Revenues Adjusted Group EBITDA significant participation in € m in € m 30 100+ 128 446.4 9 123.1 Co-owned companies Top-class employees Unpartnered R&D programmes 0 14 1,000 3,030 10 40
Slide 7: Productivity challenge will further increase
Productivity challenge will further increase Development costs vs. average peak sales Development cost, $ m Peak sales, $ m +67% 1,981 1,188 816 -55% 367 2010 2019 2010 2019 Cost per asset increased ~2/3rd since 2010 Average sales more than halved since 2010 PAGE 6 Source: Deloitte’s Centre for Heal
Slide 8: Variable processes drive productivity and speed
Variable processes drive productivity and speed R&D outsourcing & External Innovation in € bn ~30-38 ~85-90 ~10 100% 90% 80% ~54 ~5 70% (~60%) (~50%) ~7 60% (~70%) ~25 Capital (~90%) ∑ 50% Elasticity € ~140 bn 40% 30% ~36 ~5 20% (~40%) (~50%) ~3 10% (~30%) ~3 (10%) 0% 0% 10% 20% 30% 40% 50% 60% 70%
Slide 9: Integrated processes up to IND and product supply
Integrated processes up to IND and product supply Our focus Pre- Hit- Lead Target ID/ clinical identi- optimi- Phase I Phase II Phase III Approval Market validation Tox fication sation testing PAGE 8
Slide 10: Agenda
Agenda Overview Partnered drug discovery & development Financials & Outlook PAGE 9
Slide 11: One platform, open for tailor-made business formats
One platform, open for tailor-made business formats EVT Execute & EVT Innovate Intellectual Intellectual Property with Property with Partners Evotec PAGE 10
Slide 12: Best expertise and learning curves in all processes
Best expertise and learning curves in all processes “The Sharing Economy” for external innovation services PAGE 11
Slide 13: Higher speed and efficiency on the R&D Autobahn to Cure
Higher speed and efficiency on the “R&D Autobahn to Cure” All modality Autobahn PAGE 12
Slide 14: Better biologics with next generation technologies
Better biologics with next generation technologies Just – Evotec Biologics Highest Quality Higher Speed Integrated Design Approach Cost Efficiency Flexible Capacity PAGE 13
Slide 15: Portfolio across all modalities steadily growing
Portfolio across all modalities steadily growing Our co-owned pipeline of assets Number of projects (owned/co-owned) Small molecules Biologics Gene & Cell therapies Discovery >10 >10 >50 Pre-clinical 3 10 15 Clinical – – 15 Example iPSC HBV Cure P2x3 – derived beta immune A pipeline in cell therapy
Slide 16: Fully invested pipeline, gaining visibility
Fully invested pipeline, gaining visibility Partnership portfolio pre-clinical and clinical Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II Phase III EVT201 Insomnia (GABA-A) BAY-1817080 Chronic cough (P2X3) CT7001 Oncology (CDK7) CT7001 Oncology (CDK7) BAY-18170
Slide 17: >100 discovery projects are progressing rapidly
>100 discovery projects are progressing rapidly Partnership research and discovery portfolio Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II Phase III 1) Various ND Nephrology 1) ND Nephrology 1) ND PCOS INDY inhibitor Metabolic Various Oncology 1) ND Oncology ND
Slide 18: Re-define health and disease via comprehensive clinical and molecular profiling
Re-define health and disease via comprehensive clinical and molecular profiling The foundation of precision medicine Kidney CNS Multiple Rare Diseases Diseases Lung & Multiple Cancers Tuberculosis Women‘s Infectious Health Diseases PAGE 17 PanOmics Platform: Genomics, Transcriptomics, Proteomics and
Slide 19: Patient-derived assays as new gold standard
Patient-derived assays as new gold standard World-leading iPSC processes and network “IPS cells are a powerful tool to cure intractable diseases because they can be made from patients’ somatic cells.” Shinya Yamanaka, Nobel prize laureate Disease-specific drugs Screening Patient Disease Patient- in
Slide 20: BRIDGEs to link academia with industry
BRIDGEs to link academia with industry Long-term optionality with efficient translation Basic Applied Technology Development Product Commercialisation Market Entry & Research Research and Demonstration and Market Development Market Volume Public Market Funding Level Pension Plan Project Finance Gove
Slide 21: Agenda
Agenda Overview Partnered drug discovery & development Financials & Outlook PAGE 20
Slide 22: Strong long-term growth strategy
Strong long-term growth strategy Financial history 2016-2020 (e) – Selected performance indicators Strong revenue growth (in € m) Adjusted Group EBITDA2) (in € m) 446.9 440 - 480 375.4 123.1 100 - 120 95.5 263.8 57.2 2017 2018 2019 2020(e) 2017 2018 2019 2020(e) High-value unpartnered R&D3) (in € m)
Slide 23: Solid financial performance
Solid financial performance Condensed income statement H1 2020 – Evotec SE and subsidiaries in € m1) H1 2020 H1 2019 % vs. 2019 Strong performance across all Revenues from contracts with customers 231.0 207.1 12 business lines despite loss of Sanofi payments (€ 7.5 m); Just – Evotec Gross margin 2
Slide 24: Strong year ahead – mastering all challenges
Strong year ahead – mastering all challenges Guidance 2020 Good top-line Total Group revenues expected to range from € 440 – 480 m, despite loss of € 20 m subsidy 1 growth expected from Sanofi, and certain COVID-19 challenges1) Adjusted Group EBITDA2) expected to be in the range of € 100 – 120 m, at
Slide 25: Your contact:
#REScARCHNEVERSTOPS
Slide 26: Your contact: Enno Spillner, Chief Financial Officer
Your contact: Enno Spillner Chief Financial Officer +49.(0).40.560 81-238 +49.(0).40.560 81-333 Fax enno.spillner@evotec.com